Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Thyroid Gland Medullary Carcinoma”

73 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 73 results

Early research (Phase 1)WithdrawnNCT02831179
What this trial is testing

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Who this might be right for
Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMerkel Cell Carcinoma+26 more
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT03838692
What this trial is testing

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Antonio Fojo
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Testing effectiveness (Phase 2)Study completedNCT00121628
What this trial is testing

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer
Amgen 184
Not applicableLooking for participantsNCT04216732
What this trial is testing

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Who this might be right for
Advanced Thyroid Gland Medullary CarcinomaStage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8+3 more
M.D. Anderson Cancer Center 2,030
Testing effectiveness (Phase 2)Study completedNCT00358956
What this trial is testing

Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 19
Early research (Phase 1)Study completedNCT01155258
What this trial is testing

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Who this might be right for
Extensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more
University of Southern California 19
Large-scale testing (Phase 3)Study completedNCT00410761
What this trial is testing

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 331
Early research (Phase 1)Study completedNCT00004074
What this trial is testing

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Who this might be right for
Advanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone Metastases+124 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT00005647
What this trial is testing

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Who this might be right for
Head and Neck Cancer
Case Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)WithdrawnNCT01736878
What this trial is testing

Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma

Who this might be right for
Medullary Thyroid Carcinoma
Eanm Research Ltd
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Not applicableApproved For MarketingNCT01683110
What this trial is testing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Exelixis
Testing effectiveness (Phase 2)Study completedNCT02114658
What this trial is testing

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Who this might be right for
Thyroid Carcinoma
Bayer 18
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Early research (Phase 1)Study completedNCT00028496
What this trial is testing

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Adenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the Pancreas+39 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Not applicableStudy completedNCT01945762
What this trial is testing

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Who this might be right for
Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
Genzyme, a Sanofi Company 31
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Load More Results